Stockreport

Kyverna Therapeutics Showcases miv-cel Data in SPS, gMG; CEO Eyes First Autoimmune CAR-T BLA [Yahoo! Finance]

Kyverna Therapeutics, Inc.  (KYTX) 
PDF autoleucel ( miv-cel met the primary endpoint at week 16 with a median 46% improvement in T25FW (81% of patients =20% improvement), sustained through 24 weeks in evaluab [Read more]